Skip Navigation


Carcinogenesis Advance Access originally published online on October 26, 2005
Carcinogenesis 2006 27(3):639-645; doi:10.1093/carcin/bgi249
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/3/639    most recent
bgi249v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Arakawa, H.
Right arrow Articles by Tang, M.-s.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arakawa, H.
Right arrow Articles by Tang, M.-s.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.27 no.3 © Oxford University Press 2005; all rights reserved.

Sequence specificity of Cr(III)–DNA adduct formation in the p53 gene: NGG sequences are preferential adduct-forming sites

Hirohumi Arakawa, Feng Wu, Max Costa, William Rom and Moon-shong Tang *

Department of Environmental Medicine, Pathology and Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA

* To whom correspondence should be addressed. Tel: +1 845 731 3585; Fax: +1 845 351 2385 Email: tang{at}env.med.nyu.edu

Hexavalent chromium [Cr(VI)] is a known etiological factor in human lung cancer. Cr(VI) exposure-related lung cancer has a high mutation incidence in the p53 gene. Upon intake in human cells Cr(VI) is reduced to Cr(III), which is able to conjugate with amino acids and consequently form either binary Cr(III)–DNA or ternary Cr(III)-amino acid–DNA adducts. Both binary and ternary Cr(III)–DNA adducts are mutagenic. We have found that the Escherichia coli nucleotide excision enzyme UvrABC nuclease is able to incise Cr(III)- and Cr(III)-histidine-modified plasmid DNA and the extent of incision is proportional to the amount of Cr(III)–DNA adducts in the plasmid. In order to determine the role of Cr(III)–DNA adducts in the mutagenesis of the p53 gene in human cancer using the UvrABC nuclease incision method, we have mapped the Cr(III)–DNA distribution in PCR DNA fragments amplified from exons 5, 7 and 8 of the p53 gene. We have found that the sequence specificities of Cr(III)–DNA and Cr(III)-histidine–DNA adducts in the p53 gene sequence are identical and that both types of adducts are preferentially formed at –NGG- sequences, including codons 245, 248 and 249, the mutational hotspots in human lung cancer. It has been found that Cr(III)–DNA adducts induce mainly G to T mutations. Therefore, these results suggest that Cr(III)–DNA adduct formation contributes to the p53 gene mutations in lung carcinogenesis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.